Cannabis

The planned notice would lift cash to US$1 and the cap to US$6 per share, and extend the current Dec. 1 expiry to Dec. 4.

The Sept. 29 plan gives cannabis operators no deadline or estimate of tax relief as the guidance project enters the new fiscal year.

Congress delayed the new 0.4-milligram finished-product threshold to Dec. 11, leaving Tilray's disclosed U.S. drink formats above it.

State approvals cleared the Oct. 1 transfer of certain Ohio operations; AYR disclosed no cash proceeds or debt relief figure.

One petition is active and the other pending review; both would let Florida medical operators sell to adults if voters approve.

The ARTG's Sept. 15 entry names Jupiter Research as manufacturer; Curaleaf also reports a Sept. 17 New Zealand WAND notification.

Colorado completed its review on Sept. 29; permit issuance requires verified warranties, and DOE mine-plan approval remains pending.

The uncontrolled Canadian trial enrolled 11 patients; seven were evaluable for pain, and validated data analysis remains underway.

Lifted Made closed the Kenosha building sale Sept. 29 and used US$841,110 to repay all its outstanding bank debt.

A Sept. 29 stay in DEA hearing docket 26-96 sets Oct. 13 for a response to a motion seeking to add the GAO report to the record.

Holders have until Oct. 23 to vote on one new share for five to 15 existing shares, nomination rules and incentive-plan entitlements.

Battle Green can require a share-funded note purchase, while Vireo can trigger one at a lower share price; the maturity route uses a future trading average.

IMC Holdings retains liabilities under a C$9.4M cap subject to mutual adjustment; direct subsidiary debts are excluded from that cap.

The cannabis banking platform expects SHFS to keep its Nasdaq ticker and round fractional holdings up when split-adjusted trading begins Sept. 30.

The perpetual, royalty-free agreement covers two brands, while a Texas launch still requires final state licensure and regulatory approval.

Blöte starts Oct. 1 as Canopy seeks German medical cannabis growth; its June quarter international cannabis revenue was C$9.6M.

The Sept. 25 charter amendment doubles common-share capacity and raises the cannabis landlord’s preferred-share ceiling without a shareholder vote.

The Sept. 25 meeting lacked quorum, leaving shareholders until 9 a.m. EDT on Oct. 23 to submit proxies before the reconvened vote.

Holders will weigh a new parent company, a Delaware move and a voting-share sunset extension as Cresco pursues a potential U.S. listing.

Curaleaf urged a signature on Sept. 23; A10698B would let regulators seek suspensions and impose daily civil penalties.

Aurora cites missing pro forma financials, a French-language notice and the mandatory 105-day deposit period in its ASC application.

Advisers voted 10 to 0 on safety and 6 to 4 on effectiveness; the FDA has not set a date for its final decision.

A 51 per cent stake in a Polish drone company remains a non-binding proposal, while the registered share sale is expected to close Sept. 24.

The Health Canada-authorized depression study plans to enroll up to 200 people, while the batch also serves Australian clinics.

The addition gives Curaleaf a second Canadian benchmark, but its Sept. 23 release does not quantify any resulting fund purchases.

Vanguard's Extended Market Index Fund, which held US$95.4 billion on Aug. 31, tracks one of the two benchmarks that took the shares in.

GROW Group will distribute the Kincardine-grown flower in Britain under Canopy's Spectrum Therapeutics medical brand.

The Under New Ownership campaign went up on Sept. 21, and Tilray says it has reopened 16 BrewDog bars since the takeover closed.

He tried to swindle his store out of US$875 worth of product

The devastating blast came one week after a local fire marshal ordered it be shut down

Britain's medical cannabis sector has been rapidly expanding

Shares rose by 18% on the TSX when the financials dropped

If successful, the combined firm would be worth about US$3 billion

Illinois laws coming into force later this year could limit their sale to strictly dispensaries